Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: Results from the Bone Marrow Transplant Survivor Study

Blood

Volumn 104, Issue 6, 2004, Pages 1898-1906

  Baker, K Scott ^a   Gurney, James G ^b   Ness, Kirsten K ^b   Bhatia, Ravi ^b   Forman, Stephen J ^b   Francisco, Liton ^b   McGlave, Philip B ^b   Robison, Leslie L ^b   Snyder, David S ^b   Weisdorf, Daniel J ^b   Bhatia, Smita ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANT SURIVOR STUDY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DONOR; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOTOR NEURON DISEASE; MOUTH DISEASE; MULTIVARIATE ANALYSIS; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OSTEOPOROSIS; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCHOOL; SENSORY DYSFUNCTION; SIBLING; SURVIVAL;

EID: 4444294637     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-1010     Document Type: Article

References (26)

1. Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98:437-457.
2. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003;102:31-35.
3. Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol. 2003;40:59-71.
4. Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med. 2001;110:339-346.
5. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155-163.
6. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971-1977.
7. Snyder DS, Negrin RS, O'Donnell MR, et al. Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase. Blood. 1994;84:1672-1679.
8. Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-2238.
9. Enright H, Daniels K, Arthur DC, et al. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant. 1996;17:537-542.
10. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood. 1994;83:3377-3383.
11. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol. 2002;20:2334-2343.
12. Socie G, Clift RA, Biaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569-3574.
13. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229-239.
14. Louie AD, Robison LL, Bogue M, Hyde S, Forman SJ, Bhatia S. Validation of self-reported complications by bone marrow transplantation survivors. Bone Marrow Transplant. 2000;25:1191-1196.
15. Anderson WN. Actuarial and actual analysis. Proceedings of the 8th Annual Western Users of SAS Software (WUSS). http://lib.sta.cmu.edu/general/Markov. sas. Accessed July 12, 2004.
16. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons; 1981.
17. Baker F, Curbow B, Wingard JR. Role retention and quality of life of bone marrow transplant survivors. Soc Sci Med. 1991;32:697-704.
18. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352-1358.
19. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19:464-471.
20. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
21. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
22. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
23. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000;95:3498-3505.
24. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
25. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070-1079.
26. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758-1766.